Emcure Pharmaceuticals (BSE: 544210, NSE: EMCURE) has announced its consolidated financial results for the fourth quarter and full year ended March 31, 2026, reporting strong growth across key business segments and crossing the US$1 billion revenue milestone for the first time.
For FY26, revenue from operations stood at ₹9,204 crore, registering a 16.6% year-on-year growth, while EBITDA rose 21.8% to ₹1,789 crore with margins at 19.4%. Adjusted PAT increased 40.9% to ₹1,008 crore.
The company’s international business continued to drive growth, rising 22.2% to ₹5,177 crore, supported by strong momentum in core markets and new product launches. Domestic sales grew 10% to ₹4,027 crore, led by the cardiac, CNS, and oncology portfolios.
In Q4 FY26, revenue grew 16.7% YoY to ₹2,470 crore, while adjusted PAT rose 36% to ₹279 crore. International business sales increased 25.7% during the quarter.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “FY26 marked a strong start to our five-year strategic plan as we crossed the US$1 billion revenue milestone. Our international business delivered robust growth, while we continued strengthening our domestic portfolio through strategic partnerships and acquisitions. We remain focused on sustainable growth, margin expansion, and building long-term value through innovation and disciplined execution.”
